We share weekly commentaries with investors on stocks in our strategies that have appreciated or dropped more than 15% in a day during the course of the week. We hope you find this commentary useful.
Intellia Therapeutics (NTLA)
Intellia Therapeutics (NTLA), a pioneer in CRISPR gene editing, closed up 50% on Monday after publishing the first-ever clinical data demonstrating the safety and efficacy of in vivo genome editing. The drug candidate, NTLA-2001, is positioned as a single-dose cure for the hereditary form of ATTR amyloidosis (hATTR), a deadly disease caused by excessive expression of the amyloid protein. NTLA-2001 works by silencing the TTR gene which, in this Phase 1 trial, reduced the amyloid buildup by nearly 87%. These data compare favorably to the current standard of care which achieves an 80% amyloid reduction through weekly injections throughout a patient’s life. These breakthrough results supercharged investor enthusiasm for companies with gene or base-editing exposure.
Verve Therapeutics (VERV), a leader in gene editing therapies for cardiovascular disorders, rose 25% and 21% on Monday and Tuesday, respectively. Intellia’s (NTLA) landmark data showing the safety and efficacy of in vivo genome editing ignited investor enthusiasm for companies like Verve that also are engaged in CRISPR genome editing.
Beam Therapeutics (BEAM), a leader in base-editing medicine, appreciated 16% on both Monday and Wednesday of this week. Intellia’s (NTLA) landmark data showing safety and efficacy of in vivo genome editing ignited investor enthusiasm for companies like Beam that also are engaged in CRISPR genome editing or base-editing.
Editas Medicine (EDIT), a premier CRISPR-based gene-editing company, traded up 23% on Wednesday. Intellia’s (NTLA) landmark data showing safety and efficacy of in vivo genome editing ignited investor enthusiasm for companies like Editas that also are engaged in CRISPR genome editing.
TuSimple (TSP), an autonomous trucking technology company, closed up nearly 16% on Monday on no particular news. Perhaps investors are learning more about the opportunity in autonomous trucking as more companies in the space go public. TuSimple’s competitors, Embark and Plus, recently went public via SPACs.